Targeted BRAF inhibitor therapy (vemurafenib, dabrafenib) is an effective, novel treatment for patients with metastatic melanoma with the V600E BRAF mutation. This therapy is associated with squamous cell carcinomas and keratoacanthomas. Granulomatous eruptions have not been previously reported.
Two patients with melanoma developed cutaneous granulomatous eruptions during targeted BRAF inhibitor therapy. In case 1, after 2 months of treatment with dabrafenib and trametinib (MEK inhibitor), a papular eruption concerning for progression of disease prompted cessation of treatment. After the histopathologic diagnosis of granulomas, the patient was treated with clobetasol ointment with resolution within days and resumption of therapy. In case 2, after 5 months of vemurafenib treatment, the patient developed a granulomatous eruption, which resolved 3 weeks after cessation of therapy.
Conclusions and Relevance
We report 2 cases of cutaneous granulomatous eruptions on treatment with targeted BRAF inhibitors, a previously unreported association. Although additional investigations are necessary to better elucidate the pathogenic mechanisms, our report includes a treatment plan that prevents unnecessary discontinuation of therapy. Given the Food and Drug Administration approval of vemurafenib for metastatic melanoma, clinicians should be aware of this possible cutaneous reaction and treatment option to optimize patient management.
A, Multiple erythematous and light brown 1 to 5-mm papules on the right inner knee. A biopsy of the papule circled in purple ink revealed metastatic melanoma. B, Multiple new inflamed, erythematous papules and plaques (left and middle arrowheads) in the area of original metastatic disease 2 months after initiation of BRAF inhibitor therapy. The initial biopsy site is still healing. The new biopsy site of a papule of the right medial thigh is circled in purple ink (right arrowhead). The other biopsy site of a similar papule on the right anterior lower leg is not seen on this photograph. C, Resolution of inflamed plaques, and fewer, smaller, less erythematous and indurated papules after 2 weeks of topical clobetasol treatment, revealing overall improvement of disease after BRAF inhibitor therapy.
Biopsy of the site shown in Figure 1B revealed granulomatous inflammation around degenerated collagen in mid-reticular dermis. No melanoma cells were identified by level sections stained with hematoxylin-eosin (H&E) and melanoma antigen recognized by T cells (MART-1) immunostain (original magnification, ×40). B, Higher magnification reveals granulomas with hybrid sarcoidal and foreign body type features encircling an edematous and degenerated focus of the reticular dermis (H&E, original magnification, ×100).
A, Biopsy revealed metastatic melanoma with a granulomatous response in the mid-reticular dermis. The granulomas are well formed with hybrid sarcoidal and foreign body type features (hematoxylin-eosin, original magnification, ×100). B, Immunohistochemical stain for melanoma antigen recognized by T cells (MART-1) highlights numerous melanocytic cells within the granulomatous area (MART-1 immunostain, original magnification, ×100).
A, Biopsy revealed granulomas present in the reticular dermis with predilection to form around blood vessels (hematoxylin-eosin [H&E], original magnification, ×40). High magnification reveals loosely arrayed granulomas composed of histiocytes, Langerhans-type multinucleated giant cells, and lymphocytes (H&E, original magnification, ×200).
Thank you for submitting a comment on this article. It will be reviewed by JAMA Dermatology editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 1
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
The Rational Clinical Examination
An 18-year-old male college student presents with group A streptococcal pharyngitis, and you...
The Rational Clinical Examination
The appearance of the rash was described in the majority of studies. However, very few physical...
All results at
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.